secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001326110-23-000121
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio restructures $470M in debt; gets $200M new capital from founder
---------------------------------------------------------------------------

- Issued $200M convertible note to Nant Capital (founder affiliate) with 3-yr term, convertible at 50% premium to market price.
- Exchanged $270M of existing debt for 209,291,936 shares of common stock, deleveraging balance sheet.
- Extended $535M in debt maturities from Dec 2023 to Dec 2024.
- Net proceeds of ~$199M to fund regulatory, pre-commercialization for Anktiva (N-803) in bladder cancer.
- All transactions are related-party with Dr. Patrick Soon-Shiong, Executive Chairman and Global CSMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/0001326110-23-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000121/ibrx-20230911.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer